Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 13, 2014 - Issue 7
Submit an article Journal homepage
430
Views
14
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

A drug safety evaluation of rituximab and risk of hepatitis B

Peter RiedellWashington University School of Medicine, Division of Oncology, Department of Medicine, 660 S. Euclid Ave, Campus Box 8056, St. Louis, MO 63110, USA+1 314 362 0492; +1 314 747 5123; [email protected]
&
Kenneth R CarsonWashington University School of Medicine, Division of Oncology, Department of Medicine, 660 S. Euclid Ave, Campus Box 8056, St. Louis, MO 63110, USA+1 314 362 0492; +1 314 747 5123; [email protected]
, MD
Pages 977-987 | Published online: 12 May 2014

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sidhant Jain & Sahil Kumar. (2020) Cancer immunotherapy: dawn of the death of cancer?. International Reviews of Immunology 39:5, pages 205-222.
Read now

Articles from other publishers (13)

Namrata Singh, Vithal Madhira, Chen Hu, Amy L. Olex, Timothy Bergquist, Kathryn C. Fitzgerald, Jared D. Huling, Rena C. Patel & Jasvinder A. Singh. (2023) Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Seminars in Arthritis and Rheumatism 58, pages 152149.
Crossref
Thomas Zander & Michael Hallek. (2022) Was muss der Internist bei Patienten unter Biologikabehandlung beachten?What should specialist in internal medicine be aware of in patients treated with biologics?. rheuma plus 21:5, pages 268-273.
Crossref
Thomas Zander & Michael Hallek. (2022) Was muss der Internist bei Patienten unter Biologikabehandlung beachten?What should specialist in internal medicine be aware of in patients treated with biologics?. Der Internist 63:2, pages 165-170.
Crossref
Takako Inoue, Takeshi Matsui & Yasuhito Tanaka. (2021) Novel strategies for the early diagnosis of hepatitis B virus reactivation. Hepatology Research 51:10, pages 1033-1043.
Crossref
Leanna Wise & William Stohl. 2021. Lahita's Systemic Lupus Erythematosus. Lahita's Systemic Lupus Erythematosus 623 659 .
Florian MORETTO, François-Xavier CATHERINE, Clémentine ESTEVE, Mathieu BLOT & Lionel PIROTH. (2020) Isolated Anti-HBc: Significance and Management. Journal of Clinical Medicine 9:1, pages 202.
Crossref
Barbara Eichhorst & Michael Hallek. 2019. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 69 77 .
Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, Ming-Zhi Zhang, Wei Li, Yu Hu, Xiao-Hong Zhang, Yu-Huan Gao, Zuo-Xing Niu, Ru Feng, Wei Wang, Jie-Wen Peng, Xiao-Lin Li, Xue-Nong Ouyang, Chang-Ping Wu, Wei-Jing Zhang, Yun Zeng, Zhen Xiao, Ying-Min Liang, Yong-Zhi Zhuang, Ji-Shi Wang, Zi-Min Sun, Hai Bai, Tong-Jian Cui & Ji-Feng Feng. (2018) Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China. Chinese Medical Journal 131:15, pages 1767-1775.
Crossref
Michael HallekBruce D. ChesonDaniel CatovskyFederico Caligaris-CappioGuillermo DighieroHartmut DöhnerPeter HillmenMichael KeatingEmili MontserratNicholas ChiorazziStephan StilgenbauerKanti R. RaiJohn C. ByrdBarbara EichhorstSusan O’BrienTadeusz RobakJohn F. Seymour & Thomas J. Kipps. (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:25, pages 2745-2760.
Crossref
Kyle Amber & Michael Hertl. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology 767 774 .
Enno Schmidt & Richard Groves. 2016. Rook's Textbook of Dermatology, Ninth Edition. Rook's Textbook of Dermatology, Ninth Edition 1 74 .
Samir DaliaYaman SuleimanDavid W. CroyLubomir Sokol. (2015) Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. Cancer Control 22:3, pages 360-365.
Crossref
Dalal AlDeghaither, Brandon G. Smaglo & Louis M. Weiner. (2015) Beyond peptides and mAbs-current status and future perspectives for biotherapeutics with novel constructs. The Journal of Clinical Pharmacology 55:S3, pages S4-S20.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.